Funding sources This study was sponsored by the ProMD Biotech Co., Ltd., Tainan, Taiwan.
Lactobacillus salivarius plus fructo-oligosaccharide is superior to fructo-oligosaccharide alone for treating children with moderate to severe atopic dermatitis: a double-blind, randomized, clinical trial of efficacy and safety
Version of Record online: 6 DEC 2011
© 2011 The Authors. BJD © 2011 British Association of Dermatologists
British Journal of Dermatology
Volume 166, Issue 1, pages 129–136, January 2012
How to Cite
Wu, K.-G., Li, T.-H. and Peng, H.-J. (2012), Lactobacillus salivarius plus fructo-oligosaccharide is superior to fructo-oligosaccharide alone for treating children with moderate to severe atopic dermatitis: a double-blind, randomized, clinical trial of efficacy and safety. British Journal of Dermatology, 166: 129–136. doi: 10.1111/j.1365-2133.2011.10596.x
Conflicts of interest Tapei Veterans General Hospital Authority has a contract with ProMD Biotech Co. ProMD Biotech Co. provided all the study costs, including those for synbiotics, prebiotics, topical steroids and/or topical calcineurin inhibitors, outpatient clinic visit fees and all costs for laboratory tests. None of the authors of this study received any financial support from ProMD Biotech Co.
- Issue online: 27 DEC 2011
- Version of Record online: 6 DEC 2011
- Accepted manuscript online: 6 SEP 2011 06:26AM EST
- Accepted for publication 22 August 2011
Background Some probiotics can ameliorate childhood atopic dermatitis (AD). Prebiotics have also shown some efficacy, although when combined with probiotics as synbiotics, their efficacy may improve.
Objective We compared the effects of Lactobacillus salivarius and fructo-oligosaccharide (synbiotic) with fructo-oligosaccharide alone (prebiotic) on children with moderate to severe AD.
Methods We randomly assigned 60 children aged 2–14 years with moderate to severe AD [SCORing AD (SCORAD) > 25] to a treatment (synbiotic) or a control (prebiotic) group (30 per group). They received one capsule twice daily for 8 weeks containing either L. salivarius plus fructo-oligosaccharide (treatment) or fructo-oligosaccharide only (control). SCORAD indices were monitored at weeks 0, 4, 8 and 10 (post-treatment). Laboratory results and AD medication use were also monitored.
Results Baseline demographic and clinical characteristics and SCORAD scores were similar between the two groups. At 8 weeks, the treatment group SCORAD scores (27·4 ± 12·7) were significantly lower than for the controls (36·3 ± 14·9) (P = 0·022); this difference remained at 10 weeks. At 8 weeks, treatment group AD intensity was significantly lower (P = 0·013); more children had mild AD in the treatment group (52%; 14/27) than the control group (30%; 8/27) (P = 0·024). Medication use frequency and eosinophil cationic protein levels were significantly reduced in the treatment group at 8 weeks compared with 4 weeks.
Conclusion A synbiotic combination of L. salivarius plus fructo-oligosaccharide is superior to the prebiotic alone for treating moderate to severe childhood AD. However, continued follow-up will be necessary to ascertain long-term benefits.